After recently taking steps to undo messaging about a rival product in the European Union, CSL Vifor is carrying its amends ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated ...

With EuroAPI’s restructuring plan underway, the Sanofi spinoff has pulled a new CEO from within its ranks to guide the ...

Apparently, it takes three to bring Boehringer Ingelheim and Eli Lilly’s joint “It Takes 2” initiative to the annual ...

In a 60 million euro ($63 million) expansion project, BioMarin is adding a new four-story laboratory to its Shanbally ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

A new survey from AbbVie digs into the emotional experience of a chronic lymphocytic leukemia (CLL) diagnosis and, according ...

With the China-targeting Biosecure Act absent from a key defense spending bill revealed over the weekend, it appears the ...

Ten years after its first FDA approval, Amgen’s Blincyto continues to make inroads in treating acute lymphoblastic leukemia. | Investigators halted study randomization early based on the strong ...

Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...